AEDs and psychotropic drugs in children with autism and epilepsy

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 10, Issue 2, 2004, Pages 135-138

  Tuchman, Roberto ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Dan Marino Center   (United States)

Author keywords

AEDs; Autism; Epilepsy; Psychotropics; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROIC ACID;

AGGRESSION; AGITATION; APPETITE DISORDER; BEHAVIOR DISORDER; CHILD; COMPULSION; DRUG EFFICACY; DYSKINESIA; ELECTRIC ACTIVITY; EPILEPSY; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INFANTILE AUTISM; INSOMNIA; IRRITABILITY; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SIDE EFFECT; STEREOTYPY; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ANTICONVULSANTS; AUTISTIC DISORDER; BRAIN; CHILD; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; PSYCHOTROPIC DRUGS;

EID: 4944251850     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrdd.20026     Document Type: Review

References (73)

1. Aldenkamp AP, Arends J. 2004. Effects of epileptiform EEG discharges on cognitive function: Is the concept of "transient cognitive impairment" still valid? Epilepsy Behav 5(Suppl 1): S25-S34.
2. Aman MG, Van Bourgondien ME, Wolford PL, et al. 1995. Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. J Am Acad Child Adolesc Psychiat 34(12):1672-1681.
3. Anderson LT, Campbell M, Adams P et al. 1989. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19(2):227-239.
4. Arnold LE, Aman MG, Martin A, et al. 2000. Assessment in multisite randomized clinical trials of patients with autistic disorder: The Autism RUPP Network, Research Units on Pediatric Psychopharmacology. J Autism Dev Disord 30(2):99-111.
5. Arnold LE, Vitiello B, McDougle C et al. 2003. Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. J Am Acad Child Adolesc Psychiat 42(12):1443-1450.
6. Ballaban-Gil K, Tuchman K. 2000. Epilepsy and epileptiform EEG: Association with autism and language disorders. Ment Retard Dev Disabil Res Rev 6(4):300-308.
7. Bauman ML, Kemper TL. 2003. The neuropathology of the autism spectrum disorders: What have we learned?. Novartis Found Symp 251:112-122; discussion 122-118:281-197.
8. Belsito KM, Law PA, Kirk KS, et al. 2001. Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 31(2):175-181.
9. Blatt GJ, Fitzgerald CM, Guptill JT, et al. 2001. Density and distribution of hippocampal neurotransmitter receptors in autism: An autoradiographic study. J Autism Dev Disord 31(6): 537-543.
10. Brambilla P, Hardan A, di Nemi SU, et al. 2003. Brain anatomy and development in autism: Review of structural MRI studies. Brain Res Bull 61(6):557-569.
11. Branford D, Bhaumik S, Naik B. 1998. Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. J Intellect Disabil Res 42(4):301-306.
12. Buitelaar JK. 2003. Why have drug treatments been so disappointing? Novartis Found Symp 251:235-244; discussion 245-239:281-297.
13. Buitelaar JK, Dekker ME, van Ree JM, et al. 1996. A controlled trial with ORG 2766, an ACTH-(4-9) analog, in 50 relatively able children with autism. Eur Neuropsychopharmacol 6(1):13-19.
14. Bundey S, Hardy C, Vickers S, et al. 1994. Duplication of the 15q11-13 region in a patient with autism, epilepsy and ataxia. Dev Med Child Neurol 36(8):736-742.
15. Campbell M, Anderson LT, Small AM et al. 1990. Naltrexone in autistic children: A double-blind and placebo-controlled study. Psychopharmacol Bull 26(1):130-135.
16. Campbell M, Armenteros JL, Malone RP et al. 1997. Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36(6):835-843.
17. Casanova MF, Buxhoeveden D, Gomez J. 2003. Disruption in the inhibitory architecture of the cell minicolumn: Implications for autism. Neuroscientist 9(6):496-507.
18. Chez MG, Buchanan cerebral palsy (CP), Aimonovitch MC et al. 2002. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 17(11):833-837.
19. Childs JA, Blair JL. 1997. Valproic acid treatment of epilepsy in autistic twins. J Neurosci Nurs 29(4):244-248.
20. Chugani DC. 2002. Role of altered brain serotonin mechanisms in autism. Mol Psychiatry 7(Suppl 2):S16-S17.
21. Cook EH. 1990. Autism: Review of neurochemical investigation. Synapse 6(3):292-308.
22. Coplan J, Souders MC, Mulberg AE, et al. 2003. Children with autistic spectrum disorders. II: Parents are unable to distinguish secretin from placebo under double-blind conditions. Arch Dis Child 88(8):737-739.
23. DeLong GR, Teague LA, McSwain Kamran M. 1998. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 40(8):551-562.
24. Devinsky O. 2003. Psychiatric comorbidity in patients with epilepsy: Implications for diagnosis and treatment. Epilepsy Behav 4(Suppl 4):S2-S10.
25. Di Martino A, Tuchman RF. 2001. Antiepileptic drugs: Affective use in autism spectrum disorders. Pediatr Neurol 25(3):199-207.
26. Fankhauser MP, Karumanchi VC, German ML, et al. 1992. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53(3):77-82.
27. Feldman HM, Kolmen BK, Gonzaga AM. 1999. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiat 38(5):587-593.
28. Fillano JJ, Goldenthal MJ, Rhodes CH, et al. 2002. Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome. J Child Neurol 17(6):435-439.
29. Findling RL, Maxwell K, Scotese-Wojtila L, et al. 1997. High-dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord 27(4):467-478.
30. French JA, Kanner AM, Bautista J, et al. 2004a. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62(8): 1252-1260.
31. French JA, Kanner AM, Bautista J, et al. 2004b. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62(8): 1261-1273.
32. Geller E, Ritvo ER, Freeman BJ et al. 1982. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 307(3):165-169.
33. Gordon CT, State RC, Nelson JE, et al. 1993. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiat 50(6): 441-447.
34. Gram L, Bentsen KD, Parnas J, et al. 1982. Controlled trials in epilepsy: A review. Epilepsia 23(5):491-519.
35. Gurrieri F, Battaglia A, Torrisi L, et al. 1999. Pervasive developmental disorder and epilepsy due to maternally derived duplication of 15q11-q13. Neurology 52(8):1694-1697.
36. Handen BL, Johnson CR, Lubetsky M. 2000. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30(3):245-255.
37. Hollander E, Dolgoff-Kaspar R, Cartwright C, et al. 2001. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiat 62(7):530-534.
38. Jaselskis CA, Cook EH Jr, Fletcher KE, et al. 1992. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12(5):322-327.
39. Jobe PC. 2004. Affective disorder and epilepsy comorbidity: Implications for development of treatments, preventions and diagnostic approaches. Clin EEG Neurosci 35(1):53-68.
40. Ketter TA, Manji HK, Post RM. 2003. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 23(5):484-495.
41. King BH, Wright DM, Handen BL, et al. 2001. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiat 40(6):658-665.
42. Leventhal BL, Cook EH Jr, Morford M, et al. 1993. Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiat Clin Neurosci 5(3):307-315.
43. Levy SE, Souders MC, Wray J, et al. 2003. Children with autistic spectrum disorders I: Comparison of placebo and single dose of human synthetic secretin. Arch Dis Child 88(8):731-736.
44. Lewine JD, Andrews R, Chez M et al. 1999. Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders. Pediatrics 104(3/1): 405-418.
45. Manji HK, Moore GJ, Chen G. 2000. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: Implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiat 48(8):740-754.
46. Mantovani JF. 2000. Autistic regression and Landau-Kleffner syndrome: Progress or confusion? Dev Med Child Neurol 42(5):349-353.
47. McClellan JM, Werry JS. 2003. Evidence-based treatments in child and adolescent psychiatry: An inventory. J Am Acad Child Adolesc Psychiat 42(12):1388-1400.
48. McCracken JT, McGough J, Shah B, et al. 2002. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347(5):314-321.
49. McDougle CJ, Naylor ST, Cohen DJ, et al. 1996. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiat 53(11):1001-1008.
50. McDougle CJ, Scahill L, McCracken JT, et al. 2000. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 9(1):201-224.
51. McDougle CJ, Stigler KA, Posey DJ. 2003. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiat 64(Suppl 4):16-25.
52. Nass R, Gross A, Wisoff J, et al. 1999. Outcome of multiple subpial transections for autistic epileptiform regression. Pediatr Neurol 21(1): 464-470.
53. Nass R, Petrucha D. 1990. Acquired aphasia with convulsive disorder: A pervasive developmental disorder variant. J Child Neurol 5(4): 327-328.
54. Neville BG, Harkness WF, Cross JH, et al. 1997. Surgical treatment of severe autistic regression in childhood epilepsy. Pediatr Neurol 16(2): 137-140.
55. Perry EK, Lee ML, Martin-Ruiz CM, et al. 2001. Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. Am J Psychiat 158(7):1058-1066.
56. Pisani F, Oteri G, Costa C, et al. 2002. Effects of psychotropic drugs on seizure threshold. Drug Saf 25(2):91-10.
57. Pitkanen A, Kubova H. 2004. Antiepileptic drugs in neuroprotection. Expert Opin Pharmacother 5(4):777-798.
58. Plioplys AV. 1994. Autism: Electroencephalogram abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med 148(2):220-222.
59. Posey DJ, McDougle CJ. 2001. Pharmacotherapeutic management of autism. Expert Opin Pharmacother 2(4):587-600.
60. Quintana H, Birmaher B, Stedge D, et al. 1995. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25(3):283-294.
61. Remington G, Sloman L, Konstantareas M, et al. 2001. Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 21(4):440-444.
62. Rossi PG, Parmeggiani A, Bach V, et al. 1995. EEG features and epilepsy in patients with autism. Brain Dev 17(3):169-174.
63. Snead RW, Boon F, Presberg J. 1994. Paroxetine for self-injurious behavior. J Am Acad Child Adolesc Psychiat 33(6):909-910.
64. Sovner R. 1989. The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. J Clin Psychiat 50(Suppl):40-43.
65. Steingard RJ, Zimnitzky B, DeMaso DR, et al. 1997. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 7(1):9-15.
66. Strauss WL, Unis AS, Cowan C, et al. 2002. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am J Psychiat 159(5): 755-760.
67. Szabo CA, Wyllie E, Dolske M, et al. 1999. Epilepsy surgery in children with pervasive developmental disorder. Pediatr Neurol 20(5): 349-353.
68. Tuchman R. 2003. Autism. Neurol Clin 21(4): 915-932, viii.
69. Tuchman R, Rapin I. 2002. Epilepsy in autism. Lancet Neurol 1(6):352-358.
70. Tuchman RF, Rapin I, Shinnar S. 1991. Autistic and dysphasic children II: Epilepsy. Pediatrics 88(6):1219-1225.
71. Uvebrant P, Bauziene R. 1994. Intractable epilepsy in children: The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 25(6):284-289.
72. Whitaker-Azmitia PM. 2001. Serotonin and brain development: Role in human developmental diseases. Brain Res Bull 56(5):479-485.
73. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, et al. 1995. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiat 52(9):766-773.